Atjaunināt sīkdatņu piekrišanu

E-grāmata: Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

Edited by
  • Formāts: PDF+DRM
  • Izdošanas datums: 03-Mar-2013
  • Izdevniecība: Springer-Verlag New York Inc.
  • Valoda: eng
  • ISBN-13: 9781461453802
  • Formāts - PDF+DRM
  • Cena: 213,54 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: PDF+DRM
  • Izdošanas datums: 03-Mar-2013
  • Izdevniecība: Springer-Verlag New York Inc.
  • Valoda: eng
  • ISBN-13: 9781461453802

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Development of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations—many of which will be nanoparticulates—can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies.?

This book outlines the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. Coverage includes clinical evaluations with these novel vaccine technologies.
Section I Novel Immune Potentiators and Delivery Systems for Enhancing Vaccine Potency
1 TLR7/8 Agonists as Vaccine Adjuvants
3(16)
Mark A. Tomai
John P. Vasilakos
2 Preclinical and Clinical Development of Synthetic iNKT-Cell Glycolipid Agonists as Vaccine Adjuvants
19(46)
Josianne Nitcheu
Sandrine Crabe
Gwyn Davies
Vincent Serra
3 Mucosal Vaccination: Opportunities and Challenges
65(16)
Olga Borges
Gerrit Borchard
4 Oral Vaccination: Attenuated and Gene-Based
81(26)
Wendy Peters
Ciaran D. Scallan
Sean N. Tucker
Section II Design and Development of Next Generation Vaccines
5 Development of Biophysical Assays to Better Understand Adjuvanted Vaccine Formulation Potency and Stability
107(12)
James Chesko
Thomas Vedvick
Steve Reed
6 High Throughput Screening for Stabilizers of Vaccine Antigens
119(26)
C. Russell Middaugh
David B. Volkin
Sangeeta B. Joshi
7 Exploring Novel Analytical Tools to Improve Characterization of Vaccine Formulations
145(16)
Michele Pallaoro
8 Immunobioengineering Approaches Towards Combinatorial Delivery of Immune-Modulators and Antigens
161(24)
Ankur Singh
Pallab Pradhan
Krishnendu Roy
Section III Novel Delivery Technologies for Vaccines
9 Current Status of Electroporation Technologies for Vaccine Delivery
185(32)
Claire F. Evans
Drew Hannaman
10 Microneedles for Intradermal Vaccination: Immunopotentiation and Formulation Aspects
217(16)
Alexander K. Andrianov
11 MicroCor® Transdermal Delivery System: A Safe, Efficient, and Convenient Transdermal System for Vaccine Administration
233(12)
Parminder Singh
Guohua Chen
Wade Worsham
12 Mimopath™-Based Vaccine Delivery
245(24)
Kees Leenhouts
Section IV Novel Particulate Delivery Systems for Vaccines and Adjuvants
13 NanoBio™ Nanoemulsion for Mucosal Vaccine Delivery
269(18)
Tarek Hamouda
Jakub Simon
Ali Fattom
James Baker
14 Influenza Virosomes as Antigen Delivery System
287(22)
Christian Moser
Mario Amacker
15 Matrix M Adjuvant Technology
309(14)
Karin Lovgren Bengtsson
Section V Safety Assessment of Next Generation Vaccines
16 Strategies for the Nonclinical Safety Assessment of Vaccines
323(28)
Jayanthi J. Wolf
Lisa M. Plitnick
Danuta J. Herzyk
17 Safety Challenges Facing Next Generation Vaccines and the Role for Biomarkers
351(14)
S. Sohail Ahmed
Ernesto Oviedo-Orta
Jeffrey Ulmer
Index 365